Arbeitsgruppe Hepatobiliäre Tumoren - Studien
Cholangiokarzinom, Erstlinie

AIO-Studie   www.clinicaltrials.gov zur Studie

AIO-YMO/HEP-0315: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial (NIFE)
  ---in Vorbereitung---
Cholangiozelluläres Karzinom, Zweitlinie

AIO-Studie   www.clinicaltrials.gov zur Studie

AIO-HEP-0116: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine or gemcitabine containing therapies (NALIRICC)
  ---in Vorbereitung---
Cholangiokarzinom (intra- und extrahepatisch), Gallenblasenkarzinom, Zweitlinie

AIO-Studie     zur Studie

AIO-YMO/HEP-0316: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study (IRIBIL)
---in Vorbereitung---
Cholangiozelluläres Karzinom

AIO-assoziierte Studie   www.clinicaltrials.gov zur Studie

AIO-HEP-0112/ass: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial
---in Rekrutierung---